Astrocytoma Idh Mutant Grade 3 C4289981
Astrocytoma IDH mutant grade 3 is a type of brain tumor that arises from star-shaped brain cells called astrocytes. This cancer affects adults and is considered high-grade, requiring surgery, radiation, and chemotherapy. Prognosis varies based on factors like tumor location and patient age.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
New-onset seizures
Persistent headache with nausea
Focal neurological deficit
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Cognitive decline
(neurological)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Drug therapy and clinical monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Maximal safe resection
Aggressive surgical debulking while preserving neurological function is the cornerstone of treatment for grade 3 astrocytoma. Extent of resection significantly impacts overall survival outcomes.
Adjuvant radiation therapy
Focal radiation therapy delivered to the tumor bed and surrounding region typically beginning 4-6 weeks post-surgery. Standard dosing protocols target residual disease and microscopic spread.
Additional treatment options
Concurrent and adjuvant chemotherapy
Temozolomide chemotherapy given concurrently with radiation followed by adjuvant cycles. MGMT promoter methylation status helps predict treatment response.
procedureResponse assessment and surveillance imaging
Regular MRI imaging to assess treatment response and detect early recurrence. Initial post-treatment baseline followed by standardized surveillance intervals.
monitoringSupportive care and symptom management
Comprehensive supportive care addressing treatment-related symptoms including fatigue, cognitive changes, and emotional adjustment with referral to appropriate specialists as needed.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Astrocytoma Idh Mutant Grade 3 C4289981?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System. Neuro Oncol. 2021.
van den Bent MJ, Baumert B, Erridge SC, et al. Long-term efficacy of temozolomide versus procarbazine in patients with newly diagnosed IDH-mutant grade 3 astrocytoma. Lancet Oncol. 2022.
Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics. 2020.
Hartmann C, Hentschel B, Wick W, et al. Prognostic significance of IDH1 and MGMT promoter methylation in astrocytomas. J Clin Oncol. 2018.
Medication Comparisons
Compare medications used to treat Astrocytoma Idh Mutant Grade 3 C4289981. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy